Identification of prognostic different subgroups in triple negative breast cancer by Her2-neu protein expression.

Schmidt G, Meyberg-Solomayer G, Gerlinger C, Juhasz-Böss I, Herr D, Rody A, Liedtke C, Solomayer E (2014)

In: Archives of Gynecology and Obstetrics, 290(6).

Research article (journal)

Melanoma antigen family A identified by the bimodality index defines a subset of triple negative breast cancers as candidates for immune response augmentation.

Karn T, Pusztai L, Ruckhäberle E, Liedtke C, Müller V, Schmidt M, Metzler D, Wang J, Coombes KR, Gätje R, Hanker L, Solbach C, Ahr A, Holtrich U, Rody A, Kaufmann M (2012)

In: European Journal of Cancer, 48(1).

Research article (journal)

Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer.

Kaufmann M, von Minckwitz G, Mamounas EP, Cameron D, Carey LA, Cristofanilli M, Denkert C, Eiermann W, Gnant M, Harris JR, Karn T, Liedtke C, Mauri D, Rouzier R, Ruckhaeberle E, Semiglazov V, Symmans WF, Tutt A, Pusztai L (2012)

In: Annals of Surgical Oncology, 19(5).

Research article (journal)

Tumor angiogenesis as prognostic and predictive marker for chemotherapy dose-intensification efficacy in high-risk breast cancer patients within the WSG AM-01 trial.

In: .

Current Issues of Targeted Therapy in Metastatic Triple-Negative Breast Cancer.

In: .

Publications

Operated by

Top-Links

Identification of prognostic different subgroups in triple negative breast cancer by Her2-neu protein expression. Schmidt G, Meyberg-Solomayer G, Gerlinger C, Juhasz-Böss I, Herr D, Rody A, Liedtke C, Solomayer E (2014) In: Archives of Gynecology and Obstetrics, 290(6). Research article (journal)
Nomogramme zur Prädiktion von non-Sentinellymphknoten-(SLN)-Metastasen nach primär systemischer Therapie (PST)--die transSENTINA Substudie Liedtke C, Görlich D, Van Zee K, Korndörfer J, Bauerfeind I, Fehm T, Fleige B, Helms G, Lebeau A, Staebler A, von Minckwitz G, Untch M, Kühn T (2013) In: 33. Jahrestagung der Deutschen Gesellschaft für Senologie, München. Abstract in digital collection (conference)
Melanoma antigen family A identified by the bimodality index defines a subset of triple negative breast cancers as candidates for immune response augmentation. Karn T, Pusztai L, Ruckhäberle E, Liedtke C, Müller V, Schmidt M, Metzler D, Wang J, Coombes KR, Gätje R, Hanker L, Solbach C, Ahr A, Holtrich U, Rody A, Kaufmann M (2012) In: European Journal of Cancer, 48(1). Research article (journal)
Targeting triple-negative breast cancer by conversion into HER2-positive cancer: A novel therapeutic approach. Bernemann C, Huelsewig C, Kiesel L, Liedtke C (2012) In: Journal of Clinical Oncology, 30 S(15). Research article (journal)
Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Kaufmann M, von Minckwitz G, Mamounas EP, Cameron D, Carey LA, Cristofanilli M, Denkert C, Eiermann W, Gnant M, Harris JR, Karn T, Liedtke C, Mauri D, Rouzier R, Ruckhaeberle E, Semiglazov V, Symmans WF, Tutt A, Pusztai L (2012) In: Annals of Surgical Oncology, 19(5). Research article (journal)
Systematic analysis of in vitro chemosensitivity and mib-1 expression in molecular breast cancer subtypes. Liedtke C, Packeisen J, Hess KR, Vogt U, Kiesel L, Kersting C, Korsching E, Brandt B, Buerger H (2012) In: European Journal of Cancer, 48(13).
Tumor angiogenesis as prognostic and predictive marker for chemotherapy dose-intensification efficacy in high-risk breast cancer patients within the WSG AM-01 trial. In: .
News from the San Antonio Breast Cancer Symposium 2010 In: .
Current Issues of Targeted Therapy in Metastatic Triple-Negative Breast Cancer. In: .
THE WNT SIGNALING CASCADE AS A POTENTIAL NOVEL BIOMARKER OF TRIPLE NEGATIVE BREAST CANCER (TNBC) In: .